Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.
Monica GandhiLucas HillJanet GrochowskiAlexander NelsonCatherine A KossFrancis Mayorga-MunozJon OskarssonMary ShielsAnn AveryLaura BamfordJillian BaronWilliam R ShortCorrilynn O HilemanPublished in: Open forum infectious diseases (2024)
In this case series of 34 patients on LEN/CAB, high rates of virologic suppression (94%) were observed. Reasons for using LEN/CAB included adherence challenges and underlying resistance, mostly to NNRTIs. These data support a clinical trial of LEN/CAB among persons with NNRTI resistance.
Keyphrases
- clinical trial
- antiretroviral therapy
- hiv infected
- end stage renal disease
- study protocol
- ejection fraction
- newly diagnosed
- phase iii
- phase ii
- hiv positive
- human immunodeficiency virus
- peritoneal dialysis
- prognostic factors
- hepatitis c virus
- hiv testing
- electronic health record
- hiv aids
- type diabetes
- patient reported outcomes
- big data
- metabolic syndrome
- men who have sex with men
- machine learning
- insulin resistance
- deep learning
- artificial intelligence